Chronic progressive multiple sclerosis
Drug research and approvals for chronic progressive multiple sclerosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 37 studies of chronic progressive multiple sclerosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 37
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- A Study of IMS001 in Patients With Multiple SclerosisNCT07935031 · Phase 1 · Zhuhai Hengqin ImStem Biotechnology Co., Ltd. · starts Sep 28, 2026
- REAL-MS: Observational Database Study of AHSCT and MS TherapiesNCT07899502 · Not reported · Imperial College London · starts Oct 7, 2026
- A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple…NCT07840326 · Phase 2 · Sundance Biosciences, Inc. · starts Oct 1, 2026
- Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in…NCT07831928 · Not applicable · University of Iowa · starts Dec 15, 2026
- A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved…NCT07609719 · Phase 4 · Genentech, Inc. · starts Sep 2, 2026
- Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple SclerosisNCT07587125 · Phase 1 · Xijing Hospital · starts May 8, 2026
- Treatment of Participants With Primary or Secondary Progressive Multiple SclerosisNCT07477639 · Phase 1 / Phase 2 · Tr1X, Inc. · starts Mar 1, 2026
- Cognitive Performance, Sleep Disturbances and Fatigue in Multiple SclerosisNCT07426991 · Not reported · Heinrich-Heine University, Duesseldorf · starts Nov 1, 2024
- Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) PatientsNCT07392879 · Not applicable · University of Michigan · starts Dec 15, 2025
Approved 3
- OcrelizumabB-lymphocyte antigen CD20 binding agent
- SiponimodSphingosine 1-phosphate receptor Edg-1 agonist
- UblituximabB-lymphocyte antigen CD20 binding agent
Phase 3 12 of 17
- NatalizumabIntegrin alpha-4/beta-7 inhibitor
- SimvastatinHMG-CoA reductase inhibitor
- FingolimodSphingosine 1-phosphate receptor agonist
- TolebrutinibTyrosine-protein kinase BTK inhibitor
- Dirucotide
- MitoxantroneDNA topoisomerase II alpha inhibitor
- TeriflunomideDihydroorotate dehydrogenase inhibitor
- TerfenadineHistamine H1 receptor antagonist
- DesloratadineHistamine H1 receptor antagonist
- DiphenhydramineHistamine H1 receptor antagonist
- Methylprednisolone hemisuccinateGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
Phase 2 12 of 20
- RituximabB-lymphocyte antigen CD20 binding agent
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- ForalumabT cell surface glycoprotein CD3 inhibitor
- CladribineDNA inhibitor
- FluoxetineSerotonin transporter inhibitor
- LamotrigineSodium channel alpha subunit blocker
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- AmilorideAmiloride-sensitive sodium channel, ENaC blocker
- Glatiramer acetate
- IndapamideThiazide-sensitive sodium-chloride cotransporter inhibitor
- CorticotropinMelanocortin receptor 2 agonist
- RiluzoleSodium channel alpha subunit blocker
Phase 1 or earlier 12 of 15
- IdebenoneAntioxidant and mitochondrial electron carrier
- MethylphenidateDopamine transporter inhibitor
- LiothyronineThyroid hormone receptor agonist
- Insulin humanInsulin receptor agonist
- ClemastineHistamine H1 receptor antagonist
- Insulin porkInsulin receptor agonist
- TetracyclineBacterial 70S ribosome inhibitor
- BaminerceptHeterotrimeric lymphotoxin LTa1b2 inhibitor
- Interferon beta
- Andrographolide
- Deoxyandrographolide
- Neoandrographolide
How its trials ended
207 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 42 whose ending is known, 31% met their primary endpoint, 24% missed it and 45% stopped early.
- Completed, result not reported8039%
- Ongoing6330%
- Status unknown2211%
- Met its primary endpoint136%
- Missed its primary endpoint105%
- Stopped: other or unclear84%
- Stopped: lack of efficacy63%
- Stopped: enrollment or feasibility21%
- Stopped: sponsor or business decision21%
- Stopped: funding1<1%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Dec 9, 1985 | ColchicineFor arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis. | Pharmacontrol Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA